Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/31200
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCarretero Gomez, Juana-
dc.contributor.authorEna, Javier-
dc.contributor.authorSeguí-Ripoll, José Miguel-
dc.contributor.authorCarrasco-Sánchez, Francisco Javier-
dc.contributor.authorGómez Huelgas, Ricardo-
dc.contributor.authorMateos Polo, Lourdes-
dc.contributor.authorVarela Aguilar, Jose M.-
dc.contributor.authorSuárez Tembra, José M-
dc.contributor.authorArévalo-Lorido, José Carlos-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-02-07T10:07:46Z-
dc.date.available2024-02-07T10:07:46Z-
dc.date.created2020-06-08-
dc.identifier.citationInternational Joural of Clinical Practice. 2020 Oct;74(10):e13586es_ES
dc.identifier.issn1742-1241-
dc.identifier.issn1368-5031-
dc.identifier.urihttps://hdl.handle.net/11000/31200-
dc.description.abstractAims: We aimed to determine the efficacy and safety of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists to prevent worsening urinary albumin-to-creatinine ratio as an early biomarker of diabetes kidney disease. Methods: A total of 178 patients with type 2 diabetes and obesity received combination treatment with SGLT2i added to GLP1ra (n = 76), GLP1ra added to SGLT2i (n = 50) or GLP1ra plus SGLT2i from start (n = 52), according to investigators´ best clinical judgement. Major outcomes assessed at 26 weeks were changes in urine albumintocreatinine-ratio (UACR), estimated glomerular filtration rate (eGFR), glycated haemoglobin, body weight and systolic blood pressure. Results: All patients (58.6% men, mean age 61.9 ± 10.0 years) completed the study. Baseline HbA1c, weight and eGFR levels were 8.2 ± 0.9%, 109.9 ± 19 kg and 83.3 ± 19.6 mL/min/m2 , respectively. At 26 weeks, we found significant reductions in HbA1c (1.16%), weight (5.17 kg) and systolic blood pressure (8.13 mmHg). The reduction in UACR was 15.14 mg/g (95% CI 8.50-22.4) (-24.6 ± 64.7%), which was greatest in the group of patients with SGLT2i added on to GLP1ra therapy (116.7 mg/g; 95% CI: 54-296.5 mg/g; P < .001. Patients with urinary albumin-to-creatinine ratio ≥30 mg/g, showed a higher declines (63.18 mg/g [95% CI 44.5-104.99]) (-56 ± 65.9%). The greatest reduction in urinary albumin-to-creatinine ratio was obtained when SGLT2i was added to GLP1ra (116.7 mg/g). The eGFR did not significantly change along the study period. Conclusion: Our results show the beneficial effect of GLP1ra and SGLT2i combination therapy on early biomarkers of diabetes kidney disease such as albuminuria and in other significant outcomes for diabetes control.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent8es_ES
dc.language.isoenges_ES
dc.publisherWiley Online Libraryes_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleEarly biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agentses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1111/ijcp.13586es_ES
Appears in Collections:
Artículos Medicina Clínica


no-thumbnailView/Open:

 Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.pdf



893,78 kB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???